RxDoctor Payments Data

Alexander Korenfeld, MD

Internal Medicine · Cliffside Park, NJNPI 1063428803

Payments from drug & device makers

$1,785in general payments, 2019–2025

Across 28 payments — averaging $63.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$925
  • Boehringer Ingelheim$365
  • AbbVie$328
  • Lilly USA, LLC$125
  • Kowa Pharmaceuticals America, Inc.$28
  • GSK$15

What the payments were for

  • Food & beverage$1,75298%
  • Education$332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,785 in reported general payments places this provider in the 75th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$358,506
Medicare patients
182
Services billed
3,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium111$65,535
VascepaIcosapent Ethyl70$22,845
EliquisApixaban24$21,354
JardianceEmpagliflozin12$8,835
Icosapent Ethyl14$4,687
DexilantDexlansoprazole12$3,638
Varenicline Tartrate12$2,610
Albuterol Sulfate HfaAlbuterol Sulfate59$1,576
Esomeprazole Magnesium17$1,080
Mometasone Furoate17$923
Memantine Hcl ErMemantine Hcl18$861
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide32$860
Rosuvastatin Calcium111$664
Phenobarbital229$635
Ezetimibe15$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$365$8,83512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Cliffside Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →